Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- relative percentage of regulatory B cells among B cells in peritoneal cavity compared to peripheral blood
Study Overview
Brief Summary
Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject. In mice, the main source of those anti-inflammatory lymphocytes is the peritoneal cavity. No data are available in human. This study aims at exploring the presence of those anti-inflammatory lymphocytes in human peritoneal cavity and at determine how to expand those cells.
Detailed Description
B cells will be collected during procedures planned for patients' standard care. Peritoneal fluid and peripheral blood of patients will be collected during coelioscopy for exploration of ovarian cysts or dialysis for treatment of chronic renal insufficiency.
Regulatory B cells (Breg cells) will be measured in peritoneal fluid and in peripheral blood after in vitro stimulation and assessment of intracellular interleukin-10 by flow cytometry. Proportion of Breg cells among B cells will be compared between peritoneal fluid and peripheral blood in both groups.
Different protocols to induce differentiation of B cells into Breg cells will be tested and compared.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy
- •patient with chronic renal insufficiency undergoing peritoneal dialysis
- •informed consent obtained
Exclusion Criteria
- •pregnancy or breast-feeding
- •non affiliation to health care insurance
- •treatment with corticosteroids over 15 mg/day
- •treatment with rituximab
Arms & Interventions
subjects with ovarian cyst
Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
Intervention: peritoneal fluid and blood sample (Other)
subjects with peritoneal dialysis
Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
Intervention: peritoneal fluid and blood sample (Other)
Outcomes
Primary Outcomes
relative percentage of regulatory B cells among B cells in peritoneal cavity compared to peripheral blood
Time Frame: up to 48 hour
Comparison of Breg cell in peritoneal cavity to Breg cell in peripheral blood B
Secondary Outcomes
No secondary outcomes reported